JP2023179752A5 - - Google Patents

Download PDF

Info

Publication number
JP2023179752A5
JP2023179752A5 JP2023180474A JP2023180474A JP2023179752A5 JP 2023179752 A5 JP2023179752 A5 JP 2023179752A5 JP 2023180474 A JP2023180474 A JP 2023180474A JP 2023180474 A JP2023180474 A JP 2023180474A JP 2023179752 A5 JP2023179752 A5 JP 2023179752A5
Authority
JP
Japan
Prior art keywords
gly
linker
peptide
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023180474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023179752A (ja
JP7822577B2 (ja
Filing date
Publication date
Priority claimed from JP2018559205A external-priority patent/JP7537074B2/ja
Application filed filed Critical
Publication of JP2023179752A publication Critical patent/JP2023179752A/ja
Publication of JP2023179752A5 publication Critical patent/JP2023179752A5/ja
Application granted granted Critical
Publication of JP7822577B2 publication Critical patent/JP7822577B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023180474A 2016-05-10 2023-10-19 Cd47を活性化する作用物質およびその炎症治療における使用 Active JP7822577B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP16169072.2 2016-05-10
EP16169072 2016-05-10
EP17154452.1 2017-02-02
EP17154452 2017-02-02
JP2018559205A JP7537074B2 (ja) 2016-05-10 2017-05-10 Cd47を活性化する作用物質およびその炎症治療における使用
PCT/EP2017/061151 WO2017194586A1 (en) 2016-05-10 2017-05-10 Agents that activate cd47 and their use in the treatment of inflammation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018559205A Division JP7537074B2 (ja) 2016-05-10 2017-05-10 Cd47を活性化する作用物質およびその炎症治療における使用

Publications (3)

Publication Number Publication Date
JP2023179752A JP2023179752A (ja) 2023-12-19
JP2023179752A5 true JP2023179752A5 (https=) 2024-04-08
JP7822577B2 JP7822577B2 (ja) 2026-03-03

Family

ID=58772857

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018559205A Active JP7537074B2 (ja) 2016-05-10 2017-05-10 Cd47を活性化する作用物質およびその炎症治療における使用
JP2022035726A Pending JP2022078244A (ja) 2016-05-10 2022-03-08 Cd47を活性化する作用物質およびその炎症治療における使用
JP2023180474A Active JP7822577B2 (ja) 2016-05-10 2023-10-19 Cd47を活性化する作用物質およびその炎症治療における使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018559205A Active JP7537074B2 (ja) 2016-05-10 2017-05-10 Cd47を活性化する作用物質およびその炎症治療における使用
JP2022035726A Pending JP2022078244A (ja) 2016-05-10 2022-03-08 Cd47を活性化する作用物質およびその炎症治療における使用

Country Status (5)

Country Link
US (1) US11142548B2 (https=)
EP (1) EP3454884B1 (https=)
JP (3) JP7537074B2 (https=)
CA (1) CA3023802C (https=)
WO (1) WO2017194586A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3023802C (en) * 2016-05-10 2025-02-04 Inserm (Institut De La Sante Et De La Recherche Medicale) ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION
CN111655253A (zh) 2018-01-09 2020-09-11 杨百翰大学 用于用汉黄芩素治疗疼痛的组合物和方法
JPWO2022113887A1 (https=) * 2020-11-27 2022-06-02
EP4329825A4 (en) * 2021-04-26 2025-03-26 President and Fellows of Harvard College CD47 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE EYE DISEASES
CN116831988A (zh) * 2023-06-13 2023-10-03 南京鼓楼医院 一种载肽模拟物pkhb1的脂质体眼用制剂及其制备方法
WO2026062098A1 (fr) 2024-09-18 2026-03-26 Sorbonne Universite Nouvelles protéines activatrices de cd47

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US6001962A (en) 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
CA2226962A1 (en) * 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
EP1087993B1 (en) 1998-06-18 2008-04-02 Imed Ab Fas peptides and antibodies for modulating apoptosis
EP2479284B1 (en) 2006-07-13 2017-09-20 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
WO2010070047A1 (en) 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
WO2011008495A2 (en) 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
EP2563359A1 (en) 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
US20140127269A1 (en) 2012-02-13 2014-05-08 The Schepens Eye Research Institute, Inc. Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof
EP3434276B1 (en) 2012-06-06 2024-10-30 Pepkon Method and pharmaceutical composition for use in the treatment of cancer
US10004780B2 (en) 2012-10-17 2018-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD)
US10113169B2 (en) 2013-12-23 2018-10-30 Memorial Sloan-Kettering Cancer Center Methods and compositions for treating cancer using peptide nucleic acid-based agents
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
EP3193933B1 (en) 2014-09-17 2021-04-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd276 antibodies (b7h3)
US10016480B2 (en) 2014-10-14 2018-07-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Peptide-based methods for treating pancreatic cancer
FR3036620B1 (fr) * 2015-05-27 2017-09-01 Inst Biophytis Utilisation de 3-desoxyanthocyanidines pour le traitement de maladies oculaires
CA3023802C (en) * 2016-05-10 2025-02-04 Inserm (Institut De La Sante Et De La Recherche Medicale) ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION

Similar Documents

Publication Publication Date Title
JP2023179752A5 (https=)
JP2025063029A5 (https=)
JP2018171063A5 (https=)
JP2019122392A5 (https=)
Vitali Proline-rich peptides: Multifunctional bioactive molecules as new potential therapeutic drugs
JP2023504914A5 (https=)
JP2023518596A5 (https=)
JP2018515085A5 (https=)
JP2012520059A5 (https=)
JP2018536405A5 (https=)
CA2412278A1 (en) Polymer-modified synthetic proteins
JP2023029902A5 (https=)
JP2018538356A5 (https=)
JP2023545707A5 (https=)
JP2022126804A5 (https=)
JP2020517260A5 (https=)
JP2025504625A5 (https=)
AU2002365196B8 (en) Multimeric proteins and methods of making and using same
AU2009312892A1 (en) Neuropeptide-2-receptor (Y-2r) agonists and uses thereof
JP2010504336A5 (https=)
CN110461861A (zh) 人参肽和人参肽类似肽的制备和利用
JP2022500409A5 (https=)
JP2019521963A5 (https=)
JP2026035742A5 (https=)
EP1756160B1 (en) Oligomeric peptides and their use for the treatment of hiv infections